All In Biotech

Investigational drug · Phase 2

Lorigerlimab

Also called: MGD019

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

9

Any phase or sponsor naming "Lorigerlimab"

First trial start

2023

Sep 28, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Lorigerlimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Platinum-resistant Ovarian Cancer
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Clear Cell Adenocarcinoma of Ovary
  • Clear Cell Adenocarcinoma of Vulva
  • Clear Cell Adenocarcinoma of Vagina
  • Clear Cell Adenocarcinoma of Cervix
  • Clear Cell Adenocarcinoma of Uterus
  • Clear Cell Adenocarcinoma of Fallopian Tube
  • Clear Cell Adenocarcinoma of Peritoneum

Approved drugs for the same conditions: Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Lorigerlimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Platinum-resistant Ovarian Cancer

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • Rina-SPRO1184, GEN1184Phase 39 trials

    Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer

  • SYS6043Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma

  • ZN-c3azenosertibPhase 34 trials

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma

  • Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials

    Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer

  • TaxanePhase 33 trials

    AstraZeneca · Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer

  • NP-G2-044PrilukaePhase 32 trials

    Novita Pharmaceuticals, Inc. · Platinum-resistant Ovarian Cancer, Advanced or Metastatic Solid Tumor Malignancies

  • TILT-123Ad5, 3-E2F-d24-hTNFa-IRES-hIL2Phase 21 trial

    TILT Biotherapeutics Ltd. · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.